雅虎香港財經 Struggling 23andMe Granted Extension to Revive Stock Price
(Bloomberg) -- Embattled DNA-testing firm 23andMe Holding Co. has been granted an additional 180 days to move its shares above $1 and avoid being delisted, according to a filing with the Securities and Exchange Commission.
Most Read from Bloomberg
Putin Appoints Economist as Defense Minister in Shock Reshuffle
Trump Vows ‘Day One’ Executive Order Targeting Offshore Wind
Trump Pledges Across-the-Board Tax Cuts If He Returns to Office
The stock has traded below the $1 Nasdaq minimum since late last year, with the clock is ticking to regain compliance. It will now have until Nov. 4 to regain compliance.
23andMe agreed to go public in 2021 via a merger with a special purpose acquisition company founded by billionaire Virgin Group founder Richard Branson. It was valued at $3.5 billion at the time. In just a few years, the stock has lost more than 90% of its value as the consumer DNA testing revolution the company sought has been slow to catch on.
The company didn’t immediately respond to a request for comment.
Last month, Chief Executive Officer Anne Wojcicki said she’s considering taking the company private, telling board members she is proposing to acquire the company, according to a filing. In February, she told Bloomberg she was considering several strategies to revive the stock price, among them splitting the company’s drug-development business from its consumer spit kit business.
Most Read from Bloomberg Businessweek
©2024 Bloomberg L.P.
